Compare BridgeBio Pharma Inc (BBIO) vs Waste Management, Inc. (WM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Waste Management, Inc. — how do they compare? BridgeBio Pharma Inc trades at $84.09 (market cap $16.46B), while Waste Management, Inc. trades at $234.26 (market cap $94.08B). The key difference: Waste Management, Inc. is far larger — about 5.7× BridgeBio Pharma Inc's market cap, and Waste Management, Inc. pays a 1.51% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WM | |
|---|---|---|
Market Cap | $16.46B | $94.08B |
Sector | Health | Industrials |
52-Week High | $90.17 | $246.51 |
52-Week Low | $44.81 | $196.77 |
Enterprise Value | $18.02B | $116.81B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
WM trades at $236.71, up 1.45% today, near its 52-week high. The stock shows bullish technical signals with strong moving averages and a consensus analyst price target of $263.57. Recent earnings beat expectations in Q1 2026, with revenue growth to $25.20 billion in 2025. The company maintains solid profitability with a 10.99% net margin and offers a dividend, with the next payment scheduled for June 18, 2026.
Outlook remains positive due to pricing discipline and renewable energy initiatives, but high valuation multiples (P/E 34.26) and recent earnings misses pose risks. Institutional sentiment is bullish with no sell ratings, though debt levels have increased. Key near-term catalyst is Q2 2026 earnings release on July 28, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
